CD8A and hepatocellular carcinoma: Other cases that do not respond well to current ICI therapies can be studied further from the perspective of tumor-immune co-evolution, such as nonalcoholic steatohepatitis-related HCC, which bears special resident-like activated CD8+ cells that cause hepatocyte damage, hepatic fibrosis, and decreased anti-tumor immunity [[7], [26], [27]].